Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02335814
Title First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Flexus Biosciences, Inc.
Indications

acute myeloid leukemia

Therapies

FLX925

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Mayo Clinic Scottsdale Arizona 85259 United States Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
Mayo Clinic Cancer Center Jacksonville Florida 32224 United States Details
Northwestern University, Robert H. Lurie Comprehensive Cancer Center Chicago Illinois 60611 United States Details
University of Michigan Ann Arbor Michigan 48109 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Duke Cancer Center Durham North Carolina 27710 United States Details
University of Pennsylvania, Abramson Cancer Center Philadelphia Pennsylvania 19104 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
University of Washington/Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field